In addition, with respect to CEBPA mutated AML, ICC only includes in-frame bZIP CEBPA mutations, while WHO 2022 accepts biallelic CEBPA mutations (as in WHO 2017) as well as single mutations of any kind that are located in the bZIP region of the gene. This evidence concerns the gene CEBPA and intrahepatic cholangiocarcinoma.